首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2103014

ELISA診斷市場－策略分析與預測（2026-2035年）

ELISA Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 ELISA 診斷市場將從 2026 年的 27 億美元成長到 2035 年的 39.7 億美元，複合年成長率為 4.4%。

由於其高靈敏度、高特異性、成本效益以及在臨床診斷、生物醫學研究、藥物開發和食品安全檢測等領域的廣泛應用，全球酶聯免疫吸附試驗（ELISA）診斷市場在現代臨床檢測中繼續發揮著至關重要的作用。酵素免疫分析法（ELISA）是一種基於微孔板的免疫檢測，用於檢測和定量蛋白質、抗體、荷爾蒙、抗原、胜肽和其他生物分子。該技術已成為感染疾病、自體免疫疾病、癌症生物標記、過敏測試和治療藥物監測等領域應用最廣泛的診斷方法之一。慢性疾病和感染疾病負擔的日益加重，以及對疾病早期檢測需求的成長，正在推動該市場的持續擴張。

ELISA檢測技術在醫院、診斷檢查室、研究機構、製藥公司和生技公司的應用日益廣泛。醫療基礎設施投資的增加、檢查室自動化技術的進步以及免疫診斷技術的持續改進，正推動ELISA檢測技術在全球的普及。此外，人們對預防醫學、常規疾病篩檢和精準診斷的日益重視，也為市場參與企業創造了機會。

技術創新顯著提升了酶聯免疫吸附試驗（ELISA）的性能，包括提高了檢測靈敏度、實現了自動化、具備了多參數檢測能力以及與數位化實驗室資訊系統整合。自動化ELISA分析儀的引入減少了人工干預，提高了檢查室效率，並最大限度地減少了檢測誤差。重組抗原、單株抗體、高性能試劑和微孔盤技術的廣泛應用進一步提高了診斷準確性，並擴大了臨床應用範圍。

此外，藥物研發活動和疫苗開發項目的不斷增加，也對市場產生了積極影響。在這些項目中，ELISA 作為生物標記檢測、抗體測量、免疫抗原性評估和治療監測的關鍵分析工具發揮重要作用。對檢查室診斷檢測需求的成長，加上醫療保健支出的增加以及人們對早期疾病診斷重要性的認知不斷提高，預計將在整個預測期內支撐市場持續成長。

市場促進因素

感染疾病和慢性病發生率上升

感染疾病、自體免疫疾病、癌症、心血管疾病和代謝性疾病的日益流行，顯著推動了對可靠臨床檢測技術的需求。酵素連結免疫吸附試驗（ELISA）因其分析準確性高、臨床應用廣泛，仍是首選的診斷平台。

對疾病早期診斷的需求日益成長

醫療機構越來越重視早期診斷，以改善治療效果並降低醫療成本。利用酵素連結免疫吸附試驗（ELISA）進行的診斷測試能夠準確識別疾病特異性生物標記物，從而實現多種疾病的早期檢測。

檢查室自動化擴展

診斷檢查室正擴大採用自動化ELISA平台，以提高營運效率、縮短檢測結果報告時間並增加檢測能力。自動化還能最大限度地減少人為錯誤，同時提高檢測結果的可重複性和最佳化檢查室工作流程。

擴大醫藥和生物技術分析

ELISA仍然是藥物發現、疫苗研發、臨床研究和治療監測中至關重要的分析技術。隨著生命科學研發投入的增加，市場需求持續成長。

免疫診斷技術的進步

檢測設計、試劑品質、多參數檢測以及與數位檢查室的整合等方面的不斷改進提高了 ELISA 的性能，使其在更廣泛的診斷應用中得到應用。

市場限制因素

與先進分子診斷技術的競爭

分子診斷技術和快速概念驗證 (PoC) 測試平台的日益普及，可能會導致某些臨床應用中對傳統 ELISA 檢測的需求下降。

檢查室基礎設施需求

ELISA 檢測需要專門的檢測設備、訓練有素的負責人和受控的檢測環境，這限制了其在資源有限的醫療保健機構中的應用。

處理時間

與某些快速診斷方法相比，ELISA 檢測通常處理時間較長，需要多個步驟，這會影響高檢測量環境下的檢測效率。

嚴格的監管要求

診斷產品必須符合各種監管標準，這些標準規定了分析性能、品質保證和生產標準，這增加了產品開發成本和批准時間。

試劑和設備的成本

對高品質試劑、耗材、校準樣本和實驗室設備的持續需求，給診斷檢查室和醫療保健機構的營運成本帶來了負擔。

按ELISA類型
- 直接ELISA
- 間接ELISA
- 夾心ELISA
- 競爭性ELISA
- 其他
檢測方法
- 比色法
- 化學冷光
- 螢光法
- 其他
透過使用
- 傳染病檢查
- 瘤
- 自體免疫疾病
- 內分泌學
- 免疫學
- 其他
最終用戶
- 醫院和診斷中心
- 臨床/診斷檢查室
- 製藥和生物技術公司
- 其他

第10章：ELISA診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章 ELISA診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd
Siemens AG
Abbott Laboratories
Danaher Corporation
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific
Agilent Technologies Inc.
Becton, Dickinson and Company
Autobio Diagnostics Co., Ltd.
QuidelOrtho Corporation

第14章：ELISA診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009018

The ELISA Diagnostics Market is expected to grow at a CAGR of 4.4% from a market value of USD 2.70 billion in 2026 to USD 3.97 billion in 2035.

The global ELISA diagnostics market continues to play a vital role in modern laboratory diagnostics due to its high sensitivity, specificity, cost-effectiveness, and broad application across clinical diagnostics, biomedical research, pharmaceutical development, and food safety testing. Enzyme-Linked Immunosorbent Assay (ELISA) is a plate-based immunoassay technique used for detecting and quantifying proteins, antibodies, hormones, antigens, peptides, and other biological molecules. The technology has become one of the most widely adopted diagnostic methods for infectious diseases, autoimmune disorders, cancer biomarkers, allergy testing, and therapeutic drug monitoring. The growing burden of chronic and infectious diseases, coupled with increasing demand for early disease detection, is driving sustained market expansion.

The market is witnessing increasing adoption across hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, and biotechnology organizations. Rising investments in healthcare infrastructure, expanding laboratory automation, and continuous improvements in immunodiagnostic technologies are strengthening the adoption of ELISA-based testing worldwide. Furthermore, increasing emphasis on preventive healthcare, routine disease screening, and precision diagnostics is creating favorable opportunities for market participants.

Technological innovations have significantly enhanced ELISA performance through improved assay sensitivity, automation, multiplex testing capabilities, and integration with digital laboratory information systems. Automated ELISA analyzers have reduced manual intervention, improved laboratory productivity, and minimized testing errors. The growing use of recombinant antigens, monoclonal antibodies, high-performance reagents, and microplate technologies is further improving diagnostic accuracy and expanding clinical applications.

The market also benefits from increasing pharmaceutical research activities and vaccine development programs where ELISA serves as a critical analytical tool for biomarker detection, antibody measurement, immunogenicity assessment, and therapeutic monitoring. Growing demand for laboratory-based diagnostic testing, combined with expanding healthcare expenditure and increasing awareness regarding early disease diagnosis, is expected to support continued market growth throughout the forecast period.

Market Drivers

Rising Incidence of Infectious and Chronic Diseases

The increasing prevalence of infectious diseases, autoimmune disorders, cancer, cardiovascular diseases, and metabolic conditions is significantly driving demand for reliable laboratory diagnostic technologies. ELISA continues to be one of the preferred diagnostic platforms due to its high analytical accuracy and broad clinical applicability.

Growing Demand for Early Disease Diagnosis

Healthcare providers are increasingly emphasizing early diagnosis to improve treatment outcomes and reduce healthcare costs. ELISA-based diagnostic testing enables early detection of numerous diseases through accurate identification of disease-specific biomarkers.

Expansion of Laboratory Automation

Diagnostic laboratories are adopting automated ELISA platforms to improve operational efficiency, reduce turnaround times, and increase testing capacity. Automation also minimizes human error while improving reproducibility and laboratory workflow.

Increasing Pharmaceutical and Biotechnology Research

ELISA remains an essential analytical technology for drug discovery, vaccine development, clinical research, and therapeutic monitoring. Growing investments in life sciences research continue to expand market demand.

Advancements in Immunodiagnostic Technologies

Continuous improvements in assay design, reagent quality, multiplex testing, and digital laboratory integration are enhancing ELISA performance and expanding its use across diverse diagnostic applications.

Market Restraints

Competition from Advanced Molecular Diagnostics

The increasing adoption of molecular diagnostic technologies and rapid point-of-care testing platforms may reduce demand for conventional ELISA testing in certain clinical applications.

Requirement for Laboratory Infrastructure

ELISA testing requires specialized laboratory equipment, trained personnel, and controlled testing environments, limiting adoption in resource-constrained healthcare settings.

Longer Processing Time

Compared with certain rapid diagnostic methods, ELISA testing generally requires longer processing times and multiple procedural steps, which may affect testing efficiency in high-volume environments.

Stringent Regulatory Requirements

Diagnostic products must comply with extensive regulatory standards governing analytical performance, quality assurance, and manufacturing practices, increasing product development costs and approval timelines.

Reagent and Equipment Costs

The ongoing need for high-quality reagents, consumables, calibration materials, and laboratory instruments contributes to operational expenses for diagnostic laboratories and healthcare providers.

Technology and Segment Insights

The ELISA diagnostics market can be segmented by type, application, end user, product, and geography.

By Type

Sandwich ELISA represents a major market segment due to its excellent sensitivity and ability to accurately quantify target antigens in complex biological samples. It is widely utilized in infectious disease diagnosis, cancer biomarker analysis, and cytokine measurement.

Indirect ELISA continues to be extensively used for antibody detection in infectious disease screening and vaccine evaluation.

Competitive ELISA is commonly employed for detecting small molecules and hormones where antigen size limits the use of other assay formats.

Direct ELISA provides rapid antigen detection and remains valuable in selected research and diagnostic applications.

By Application

Disease diagnosis accounts for the largest market share owing to extensive use of ELISA for detecting infectious diseases, autoimmune disorders, endocrine diseases, allergies, and cancer biomarkers. Increasing disease prevalence continues to strengthen this segment.

Vaccine development represents another significant application where ELISA supports immunogenicity testing, antibody quantification, and vaccine efficacy assessment.

Drug monitoring applications continue to expand as pharmaceutical companies increasingly utilize ELISA for pharmacokinetic studies and therapeutic monitoring.

Food safety testing and environmental monitoring also contribute to market growth through contamination detection and quality assurance programs.

By Product

ELISA kits and reagents account for the largest product segment due to recurring laboratory demand and widespread use across diagnostic and research applications.

ELISA analyzers continue to experience steady growth as laboratories invest in automation technologies that improve efficiency and testing accuracy.

Microplates, buffers, substrates, detection antibodies, and consumables remain essential components supporting routine laboratory operations.

By End User

Hospitals and clinical laboratories represent the largest end-user segment due to increasing patient testing volumes and expanding diagnostic services.

Diagnostic centers continue to strengthen market demand through specialized laboratory testing and disease screening services.

Pharmaceutical and biotechnology companies extensively utilize ELISA throughout drug discovery, biologics development, vaccine research, and clinical trials.

Academic and research institutions contribute significantly through biomedical research, immunology studies, and translational medicine programs.

By Geography

North America maintains a leading market position due to advanced healthcare infrastructure, high diagnostic testing volumes, strong research funding, and widespread adoption of laboratory automation.

Europe continues to experience stable market growth supported by established healthcare systems and increasing investments in diagnostic innovation.

Asia Pacific is anticipated to witness the fastest growth due to expanding healthcare infrastructure, rising disease burden, increasing laboratory capacity, and growing healthcare expenditure.

Latin America and the Middle East & Africa are also expected to demonstrate gradual growth as diagnostic capabilities continue to improve.

Competitive and Strategic Outlook

The competitive landscape includes diagnostic manufacturers, biotechnology companies, life science organizations, reagent suppliers, laboratory automation providers, and medical device companies. Market participants are focusing on product innovation, assay standardization, automation technologies, multiplex immunoassays, and improved reagent performance to strengthen their competitive positions.

Companies are increasingly investing in automated ELISA platforms, artificial intelligence-enabled laboratory workflows, digital data management systems, and next-generation immunoassay technologies. Strategic collaborations between diagnostic manufacturers, research organizations, pharmaceutical companies, and healthcare providers are accelerating technological innovation and expanding product portfolios.

Market participants are also pursuing geographic expansion, regulatory approvals, product launches, mergers, and strategic partnerships to strengthen their presence across both developed and emerging markets. The continued emphasis on precision diagnostics, laboratory automation, and personalized medicine is expected to create significant growth opportunities for industry stakeholders.

Conclusion

The global ELISA diagnostics market is expected to maintain steady growth throughout the forecast period, driven by rising disease prevalence, increasing demand for early diagnosis, expanding pharmaceutical research, and continuous technological advancements in immunodiagnostics. Improvements in laboratory automation, assay sensitivity, and digital healthcare integration are enhancing the efficiency and reliability of ELISA-based testing across diverse clinical and research applications. Although competition from molecular diagnostics, regulatory complexities, and infrastructure requirements present challenges, the technology's proven accuracy, versatility, and cost-effectiveness will continue to support widespread adoption. The ELISA diagnostics market will remain an essential component of the global in vitro diagnostics industry as healthcare systems increasingly prioritize accurate disease detection, preventive care, and precision medicine.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. ELISA Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of ELISA Diagnostics
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Diagnostic Testing Landscape
3.8 Testing Volume Analysis
3.9 Disease Burden and Clinical Utility of ELISA Diagnostics
3.10 Laboratory Adoption Trends
3.11 Comparative Assessment of ELISA and Alternative Immunoassay Technologies

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging ELISA Technologies
6.2 Product Innovation
6.3 Diagnostic Assay Development Pipeline Analysis
6.4 Automation and High-Throughput ELISA Platforms
6.5 Multiplex ELISA Technologies
6.6 Microfluidic and Miniaturized ELISA Platforms
6.7 Digital Integration and Laboratory Automation
6.8 AI Integration in Immunodiagnostics
6.9 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. ELISA Diagnostics Market Landscape Analysis

8.1 Analysis by ELISA Type
8.2 Analysis by Detection Method
8.3 Analysis by Application
8.4 Analysis by End User

9. ELISA Diagnostics Market Segment Analysis (2021-2035)

9.1 By ELISA Type
- 9.1.1 Direct ELISA
- 9.1.2 Indirect ELISA
- 9.1.3 Sandwich ELISA
- 9.1.4 Competitive ELISA
- 9.1.5 Others
9.2 By Detection Method
- 9.2.1 Colorimetric
- 9.2.2 Chemiluminescent
- 9.2.3 Fluorescent
- 9.2.4 Others
9.3 By Application
- 9.3.1 Infectious Disease Testing
- 9.3.2 Oncology
- 9.3.3 Autoimmune Diseases
- 9.3.4 Endocrinology
- 9.3.5 Immunology
- 9.3.6 Others
9.4 By End User
- 9.4.1 Hospitals & Diagnostic Centers
- 9.4.2 Clinical Diagnostic Laboratories
- 9.4.3 Pharmaceutical & Biotechnology Companies
- 9.4.5 Others

10. ELISA Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. ELISA Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 China
11.10 Japan
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Mexico
11.16 Saudi Arabia
11.17 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Siemens AG
13.3 Abbott Laboratories
13.4 Danaher Corporation
13.5 Bio-Rad Laboratories, Inc.
13.6 Thermo Fisher Scientific
13.7 Agilent Technologies Inc.
13.8 Becton, Dickinson and Company
13.9 Autobio Diagnostics Co., Ltd.
13.10 QuidelOrtho Corporation